Pramipexole Exerts Beneficial Effects in a Rat Model of Acetic Acid-Induced Colitis via Modulating Inflammation
Open Access
- 1 August 2025
- journal article
- Published by Wolters Kluwer Health in Advanced Biomedical Research
- Vol. 14 (1)
Abstract
Background: Inflammatory bowel disease (IBD) is a serious public health problem worldwide. The existing therapy options for IBD are limited and can cause severe difficulties, and thus require more research on alternative therapeutic techniques. Pramipexole is a dopamine receptor agonist with anti-inflammatory effects that was recently discovered. Given the importance of dopaminergic pathways in ulcerative colitis inflammation, we tested pramipexole’s efficacy in a rat colitis model in this study. Materials and Methods: Colitis was induced by administering 3% acetic acid intrarectally. Rats were randomly assigned to one of six groups: normal, colitis control, dexamethasone (1 mg/kg; i.p.), and pramipexole (0.25, 0.5, and 1 mg/kg; i.p.). In intestinal samples, macroscopic and microscopic lesion ratings, pro-inflammatory cytokine levels (tumor necrosis factor alpha, interleukin-6, and interleukin-1 beta), and myeloperoxidase (MPO) activity were evaluated. Results: Compared to the colitis control group, pramipexole (0.5 and 1 mg/kg) substantially reduced macroscopic and microscopic intestinal damage, pro-inflammatory cytokine levels, and MPO activity. Furthermore, the indices mentioned above were considerably lower in the dexamethasone treatment group compared to the colitis control group. Conclusions: Our findings indicate that pramipexole has favorable benefits in treating experimental colitis; however, further research is required to determine its clinical value as an IBD therapeutic agent.Keywords
This publication has 32 references indexed in Scilit:
- An investigation of the anti-inflammatory effects of gabapentin on acetic acid-induced colitis in ratsMolecular Biology Reports, 2021
- Novel therapeutic targets for inflammatory bowel diseaseJournal of Autoimmunity, 2017
- Dopaminergic Regulation of Innate Immunity: a ReviewJournal of Neuroimmune Pharmacology, 2017
- Role of Dopamine and D2 Dopamine Receptor in the Pathogenesis of Inflammatory Bowel DiseaseDigestive Diseases and Sciences, 2015
- GABA and GABA receptors in the gastrointestinal tract: from motility to inflammationPharmacological Research, 2015
- Blood–brain barrier transport of pramipexole, a dopamine D2 agonistLife Sciences, 2007
- Schizophrenia, autoimmunity and immune system dysregulation: A comprehensive model updated and revisitedJournal of Autoimmunity, 2006
- Both the Antioxidant and D3 Agonist Actions of Pramipexole Mediate Its Neuroprotective Actions in Mesencephalic CulturesThe Journal of Pharmacology and Experimental Therapeutics, 1999
- Dopamine in gastrointestinal diseaseDigestive Diseases and Sciences, 1990
- The influence of dopamine agonists and antagonists on indomethacin lesions in stomach and small intestine in ratsEuropean Journal of Pharmacology, 1988